PubMed · 12697856
BRAF mutation in papillary thyroid carcinoma.
Abstract
The BRAF gene has been found to be activated by mutation in human cancers, predominantly in malignant melanoma. We tested 476 primary tumors, including 214 lung, 126 head and neck, 54 thyroid, 27 bladder, 38 cervical, and 17 prostate cancers, for the BRAF T1796A mutation by polymerase chain reaction (PCR)-restriction enzyme analysis of BRAF exon 15. In 24 (69%) of the 35 papillary thyroid carcinomas examined, we found a missense thymine (T)-->adenine (A) transversion at nucleotide 1796 in the BRAF gene (T1796A). The T1796A mutation was detected in four lung cancers and in six head and neck cancers but not in bladder, cervical, or prostate cancers. Our data suggest that activating BRAF mutations may be an important event in the development of papillary thyroid cancer.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Yoram Cohen, Mingzhao Xing, Elizabeth Mambo, Zhongmin Guo, Guogun Wu, Barry Trink, Uziel Beller, William H Westra, Paul W Ladenson, David Sidransky. 2003-04-16. BRAF mutation in papillary thyroid carcinoma.. https://doi.org/10.1093/jnci%2F95.8.625
Cite the original work for its findings. Save a collection to share your selection of sources.